What is a stock summary page? Click here for an overview.
Business Description
Predictive Oncology Inc
NAICS : 339112
SIC : 3841
ISIN : US74033P1003
Description
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.29 | |||||
| Equity-to-Asset | 0.26 | |||||
| Debt-to-Equity | 1.22 | |||||
| Debt-to-EBITDA | -0.18 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -38.15 | |||||
| Beneish M-Score | -2.86 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -40.4 | |||||
| 3-Year EBITDA Growth Rate | 44.5 | |||||
| 3-Year EPS without NRI Growth Rate | 48 | |||||
| 3-Year FCF Growth Rate | 45.8 | |||||
| 3-Year Book Growth Rate | -8.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 131.26 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 78.35 | |||||
| 9-Day RSI | 70.85 | |||||
| 14-Day RSI | 64 | |||||
| 3-1 Month Momentum % | 65.31 | |||||
| 6-1 Month Momentum % | 87.43 | |||||
| 12-1 Month Momentum % | -46.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.2 | |||||
| Quick Ratio | 1.06 | |||||
| Cash Ratio | 0.81 | |||||
| Days Inventory | 221.99 | |||||
| Days Sales Outstanding | 107.74 | |||||
| Days Payable | 629.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -60.1 | |||||
| Shareholder Yield % | -2.67 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 46.94 | |||||
| Operating Margin % | -960.19 | |||||
| Net Margin % | -920.9 | |||||
| FCF Margin % | -876.14 | |||||
| ROE % | -232.54 | |||||
| ROA % | -114 | |||||
| ROIC % | -291.56 | |||||
| 3-Year ROIIC % | 12.38 | |||||
| ROC (Joel Greenblatt) % | -408.13 | |||||
| ROCE % | -181.2 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.8 | |||||
| PB Ratio | 5.42 | |||||
| Price-to-Tangible-Book | 6.15 | |||||
| EV-to-EBIT | -0.79 | |||||
| EV-to-EBITDA | -0.84 | |||||
| EV-to-Revenue | 7.58 | |||||
| EV-to-Forward-Revenue | 0.82 | |||||
| EV-to-FCF | -0.87 | |||||
| Price-to-GF-Value | 0.44 | |||||
| Price-to-Median-PS-Value | 0.52 | |||||
| Earnings Yield (Greenblatt) % | -126.58 | |||||
| FCF Yield % | -115.28 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:POAI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Predictive Oncology Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.517 | ||
| EPS (TTM) ($) | -3.05 | ||
| Beta | 2.16 | ||
| 3-Year Sharpe Ratio | -0.31 | ||
| 3-Year Sortino Ratio | -0.48 | ||
| Volatility % | 105.05 | ||
| 14-Day RSI | 64 | ||
| 14-Day ATR ($) | 0.209935 | ||
| 20-Day SMA ($) | 1.22625 | ||
| 12-1 Month Momentum % | -46.82 | ||
| 52-Week Range ($) | 0.55 - 3.06 | ||
| Shares Outstanding (Mil) | 7.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Predictive Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Predictive Oncology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Predictive Oncology Inc Frequently Asked Questions
What is Predictive Oncology Inc(POAI)'s stock price today?
The current price of POAI is $1.60. The 52 week high of POAI is $3.06 and 52 week low is $0.55.
When is next earnings date of Predictive Oncology Inc(POAI)?
The next earnings date of Predictive Oncology Inc(POAI) is 2025-03-28 Est..
Does Predictive Oncology Inc(POAI) pay dividends? If so, how much?
Predictive Oncology Inc(POAI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers